How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Targeted Protein Degradation Market
- By Technology Platform: PROTACs (Proteolysis Targeting Chimeras), Molecular Glues, LYTACs (Lysosome Targeting Chimeras), AUTACs (Autophagy Targeting Chimeras), DUBTACs (Deubiquitinase Targeting Chimeras)
- By Target Protein Class: Kinases, Transcription Factors, Nuclear Receptors, Epigenetic Regulators, Immune Checkpoint Proteins
- By Therapeutic Application: Oncology, Neurodegenerative Diseases, Inflammatory Diseases, Infectious Diseases, Cardiovascular Diseases
- By Modality: Small Molecule Degraders, Peptide-based Degraders, Antibody-based Degraders
- By Drug Development Stage: Preclinical, Clinical Trials Phase I, Clinical Trials Phase II, Clinical Trials Phase III, Commercialized Products
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - PROTACs (Proteolysis Targeting Chimeras) leads By Technology Platform at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.183 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.191 →
Full report · locked preview
Everything inside the Targeted Protein Degradation Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Technology Platform 5
Target Protein Class 5
Therapeutic Application 5
Modality 3
Drug Development Stage 5
Companies profiled
Arvinas Inc.
C4 Therapeutics Inc.
Nurix Therapeutics Inc.
Kymera Therapeutics Inc.
Vividion Therapeutics Inc.
Foghorn Therapeutics Inc.
Monte Rosa Therapeutics Inc.
Bristol-Myers Squibb Company
Novartis AG
Amgen Inc.
Pfizer Inc.
Genentech
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Arvinas Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →C4 Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Nurix Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Kymera Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Vividion Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Foghorn Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Monte Rosa Therapeutics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Bristol-Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Novartis AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Amgen Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Genentech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Inc. (a member of the Roche Group)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Daiichi Sankyo Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Sanofi S.A.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Astellas Pharma Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,038M by 2033 · 8.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- PROTACs (Proteolysis Targeting Chimeras)30.9
- Molecular Glues12.5
- LYTACs (Lysosome Targeting Chimeras)20.8
- AUTACs (Autophagy Targeting Chimeras)21.3
- DUBTACs (Deubiquitinase Targeting Chimeras)14.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$341.4M → $597.6M · 7.2%
Europe$237.9M → $512.0M · 10.1%
Asia Pacific$217.2M → $472.7M · 10.2%
Latin America$134.5M → $274.4M · 9.3%
Middle East and Africa$103.5M → $221.9M · 10.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.812026
8.812027
8.832028
8.842029
8.842030
8.852031
8.872032
8.882033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Arvinas Inc.11.5
- C4 Therapeutics Inc.20.1
- Nurix Therapeutics Inc.10.1
- Kymera Therapeutics Inc.14.0
- Vividion Therapeutics Inc.10.7
- Foghorn Therapeutics Inc.5.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Technology Platform12.3%
Target Protein Class13.5%
Therapeutic Application25.1%
Modality24.2%
Drug Development Stage25.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America28.8
- Europe24.6
- Asia Pacific22.7
- Latin America13.2
- Middle East and Africa10.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Arvinas Inc. | 91 | 97 | 78 | 95 | 83 | 89 | 89 |
| C4 Therapeutics Inc. | 79 | 86 | 90 | 92 | 83 | 79 | 85 |
| Nurix Therapeutics Inc. | 65 | 85 | 66 | 68 | 81 | 87 | 75 |
| Kymera Therapeutics Inc. | 79 | 68 | 72 | 74 | 80 | 61 | 72 |
| Vividion Therapeutics Inc. | 65 | 65 | 72 | 62 | 70 | 60 | 66 |
| Foghorn Therapeutics Inc. | 63 | 69 | 46 | 63 | 55 | 61 | 60 |
| Monte Rosa Therapeutics Inc. | 50 | 56 | 43 | 57 | 65 | 43 | 52 |
| Bristol-Myers Squibb Company | 43 | 37 | 41 | 47 | 37 | 56 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Arvinas Inc.
- C4 Therapeutics Inc.
- Nurix Therapeutics Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Arvinas Inc. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| C4 Therapeutics Inc. | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Nurix Therapeutics Inc. | ◐ | ✓ | − | ✓ | ◐ | ✓ |
| Kymera Therapeutics Inc. | ✓ | − | ◐ | ◐ | ✓ | ◐ |
| Vividion Therapeutics Inc. | − | ◐ | ◐ | ◐ | ◐ | − |
| Foghorn Therapeutics Inc. | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| Monte Rosa Therapeutics Inc. | − | ◐ | ◐ | − | ◐ | ◐ |
| Bristol-Myers Squibb Company | − | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Arvinas Inc.89
2C4 Therapeutics Inc.85
3Nurix Therapeutics Inc.75
4Kymera Therapeutics Inc.72
5Vividion Therapeutics Inc.66
6Foghorn Therapeutics Inc.60
7Monte Rosa Therapeutics Inc.52
8Bristol-Myers Squibb Company44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Arvinas Inc.C4 Therapeutics Inc.
Challenger2
Strong scale, closing on the leaders.
Nurix Therapeutics Inc.Kymera Therapeutics Inc.
Contender2
Focused players with pockets of strength.
Vividion Therapeutics Inc.Foghorn Therapeutics Inc.
Niche2
Specialists in a single segment or region.
Monte Rosa Therapeutics Inc.Bristol-Myers Squibb Company
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Technology Platform in North America, then scale across Targeted Protein Degradation Market — a $203M beachhead inside a $2.95B market.
Beachhead (SOM)$203Mobtainable near-term
Serviceable (SAM)$1.22Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
PROTACs (Proteolysis Targeting Chimeras)
Best fit — highest urgency & budget in Technology Platform.
Economic buyer77 fit
Molecular Glues
Strong fit — clear ROI and a fast path to value.
End user69 fit
LYTACs (Lysosome Targeting Chimeras)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technology Platform in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Target Protein Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapeutic Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel31%
Digital / self-serve18%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Technology Platform leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Targeted Protein Degradation Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified21%
Evaluation15%
Closed-won5%
$11.8KCAC
$55KLTV
4.6:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Targeted Protein Degradation Market is a durable-growth opportunity — $8.34B by 2033, compounding at 8.2%.
TAM · 2025$4.42Btoday
TAM · 2033$8.34Bforecast
CAGR8.2%2027–2033
Cumulative$55.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.34BTotal addressable market
SAM$3.23BServiceable available market
SOM$668MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.2% CAGR
Demand compounds through 2033, outpacing GDP across Technology Platform.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technology Platform moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.34BLarge & growingTAM by 2033 at 8.2% CAGR
$3.23BServiceable nowreachable with today’s model
$668MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.50BBear5.4% CAGR
$8.34BBase8.2% CAGR
$10.7BBull10.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Target Protein Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Targeted Protein Degradation Market — a $5.18B market by 2033. Plan: grow share from 9.8% to 16.7%.
Market size · 2033$5.18Btotal addressable
Market CAGR7.6%2027–2033
Target share16.7%from 9.8% today
Revenue ambition$865Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.8% | 16.7% | Ahead |
| Revenue | $463M | $865M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 31.9% | 45.7% | On track |
| Customer retention | 91.8% | 94.1% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Technology Platform
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Target Protein Class capability
A defensible second engine — invest in Target Protein Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technology Platform share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Target Protein Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $115M capacity & capability investment
- Greenlight bolt-on M&A in Target Protein Class
- Authorise North America expansion plan
- Fund R&D program for Technology Platform leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Targeted Protein Degradation Market conversation — a $800M market you can size, segment and defend in minutes.
Market size · 2033$800Mtotal opportunity
Growth4.1%CAGR to 2033
Addressable buyers1,147+accounts in scope
Typical ROI5.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technology Platform
Goal Grow share in Technology Platform
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.1×return on cost, year one
< 4 mopayback period
$45K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Arvinas Inc.C4 Therapeutics Inc.Nurix Therapeutics Inc.Kymera Therapeutics Inc.Vividion Therapeutics Inc.Foghorn Therapeutics Inc.Monte Rosa Therapeutics Inc.Bristol-Myers Squibb Company+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Targeted Protein Degradation Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Targeted Protein Degradation Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Targeted Drugs for Colorectal Cancer Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportTargeted Drug Delivery Device Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportTargeted DNA Sequencing Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportTargeted Delivery Drugs Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportTargeted Antitumor Drugs Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportTardive Dystonia Treatment Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportTardive Dyskinesia Treatment Medicine Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportTaq Enzyme Monoclonal Antibody Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportTape Type Adult Diaper Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportTaper Urethral Dilator Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportTapered Needle Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportTapered Implant Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.